IL10 and acute myeloid leukemia: Furthermore, these AML-MSCs display an enhanced immunosuppressive capacity that is probably associated with increased anti-inflammatory IL-10 production, which correlates directly with patients’ overall survival, whereas AML-MSCs have reduced proinflammatory cytokine expression [134].